The estimated Net Worth of Capital Partners, Llc Tamme... is at least $19 Milione dollars as of 8 December 2017. Capital Tamme owns over 1,000,000 units of Collegium Pharmaceutical Inc stock worth over $1,651,444 and over the last 7 years Capital sold COLL stock worth over $17,340,000.
Capital has made over 1 trades of the Collegium Pharmaceutical Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Capital sold 1,000,000 units of COLL stock worth $17,340,000 on 8 December 2017.
The largest trade Capital's ever made was selling 1,000,000 units of Collegium Pharmaceutical Inc stock on 8 December 2017 worth over $17,340,000. On average, Capital trades about 1,000,000 units every 0 days since 2017. As of 8 December 2017 Capital still owns at least 45,620 units of Collegium Pharmaceutical Inc stock.
You can see the complete history of Capital Tamme stock trades at the bottom of the page.
Over the last 10 years, insiders at Collegium Pharmaceutical Inc have traded over $80,399,308 worth of Collegium Pharmaceutical Inc stock and bought 1,112,375 units worth $13,316,951 . The most active insiders traders include Group Holdings (Sbs) Adviso..., John Gordon Freund e David Hirsch. On average, Collegium Pharmaceutical Inc executives and independent directors trade stock every 35 days with the average trade being worth of $2,130,406. The most recent stock trade was executed by Shirley R. Kuhlmann on 5 September 2024, trading 20,225 units of COLL stock currently worth $773,809.
collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex
Collegium Pharmaceutical Inc executives and other stock owners filed with the SEC include: